The amendment signals acute liquidity pressure and gives the note holder near-total control over future equity capital. Monitor for potential Nasdaq delisting (cure period extension suggests non-compliance) and any restructuring or reverse split. The company's ability to raise non-dilutive capital is now effectively eliminated.
Price Chart
Executive Summary
PDS Biotechnology amended its $6M promissory note with YA II PN, Ltd., tightening repayment terms: 100% of net proceeds from any non-ATM equity financing must be paid to the holder within 5 business days, and ATM proceeds are largely swept weekly. The Nasdaq listing deficiency cure period was extended from 75 to 180 days, signaling ongoing compliance risk. The amendment reflects severe liquidity constraints and limits the company's ability to retain capital from future equity raises.
Key Facts
- Original promissory note principal: $6,000,000, issued June 15, 2026.
- Amendment requires 100% of net cash proceeds from any non-ATM equity or equity-linked financing to be paid to the holder within 5 business days.
- ATM net proceeds must be remitted weekly; excess over next installment is split 60% to holder / 40% retained by company.
- Nasdaq listing deficiency cure period extended from 75 to 180 days.
- Amendment effective upon payment of the September 14, 2026 installment amount in full.
Financial Impact
$6M promissory note represents ~50% of $12M market cap; cash flow sweep provisions severely restrict the company's ability to fund operations from equity raises.
Risk Factors
- Nasdaq delisting risk (cure period extension indicates ongoing deficiency)
- Liquidity crisis — equity raise proceeds cannot be retained for operations
- Potential default or forced restructuring if installment payments are missed
- Further dilution if the company attempts any equity-linked financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-035809 |
| Document: ef20081442_8k.htm | 0001140361-26-035809 |
| Document: 0001140361-26-035809-index-headers.html | 0001140361-26-035809 |
| Document: 0001140361-26-035809-index.html | 0001140361-26-035809 |
| Document: 0001140361-26-035809.txt | 0001140361-26-035809 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7366 (−145.53%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7366 (+252.61%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7366 (−215.87%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7366 (−186.61%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7366 (−2.95%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7366 (−18.07%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7366 (+23.27%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7366 (−27.78%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7366 (−36.50%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7366 (−44.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access